Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemothera...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Leijen, Suzanne, van Geel, Robin M.J.M., Pavlick, Anna C., Tibes, Raoul, Rosen, Lee, Razak, Albiruni R. Abdul, Lam, Raymond, Demuth, Tim, Rose, Shelonitda, Lee, Mark A., Freshwater, Tomoko, Shumway, Stuart, Liang, Li Wen, Oza, Amit M., Schellens, Jan H.M., Shapiro, Geoffrey I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2016
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7845944/
https://ncbi.nlm.nih.gov/pubmed/27601554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.5991
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi